Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

VNQI trades at $42.04, up 0.14% on the day, but technical indicators signal a bearish trend with moving averages and overall signals pointing lower. The ETF focuses on international real estate outside the U.S., offering diversification across more than 30 countries and a competitive expense ratio of 0.12%. Recent news highlights a significant drop in short interest in September 2026, suggesting reduced bearish speculation, while comparisons with peers emphasize its higher dividend yield.

The outlook remains cautious due to global real estate market volatility and bearish technicals, though reduced short interest and international exposure present opportunities for yield-seeking investors. Risks include currency fluctuations and economic downturns in foreign markets, requiring careful monitoring of macroeconomic trends for potential recovery.